
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
SkinHealth Systems is well-positioned for future success with its globally recognized brands, Hydrafacial and SkinStylus, a strong balance sheet with a cash balance of $206 million, and ongoing innovation and strategic initiatives. Despite recent challenges with execution and competition, management has taken steps to strengthen utilization and broaden growth drivers, while also maintaining a highly recurring revenue model driven by consumable sales. Risks to the company include competitive pressures, consumer demand fluctuations, and the ability to maintain brand recognition and loyalty.
Bears say
SkinHealth Systems is facing several challenges that are negatively impacting its stock's outlook. This includes declining revenue, driven by weak demand for its delivery systems and lower utilization of its consumables in key markets such as the Americas and EMEA. Additionally, management's focus on reducing costs and improving sales is taking longer than expected to show results, and there are concerns about the sustainability of the company's revenue growth. These uncertainties, along with the potential impact of regulatory risks, make it challenging to predict a sustained return to growth and justify a positive outlook on SkinHealth Systems' stock at this time.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares